Abbott Laboratories Acquires Exact Sciences

By Chris Stiles • Monday, March 23 17:11 • Permanent Link

Abbott completed its acquisition of Exact Sciences on March 23, 2026, making Exact Sciences a wholly owned subsidiary and ending trading in Exact Sciences shares on the Nasdaq on March 20.

The deal gives Abbott immediate scale in cancer screening and diagnostics, with the company saying it now has a position in the $60 billion U.S. cancer screening and precision oncology diagnostics market. Abbott said the acquisition adds a new growth vertical to its already high-single-digit growth expectations.

The combined portfolio now includes Cologuard, a noninvasive colorectal cancer screening test; Oncotype DX, used in early-stage breast cancer treatment decisions; Oncodetect, a molecular residual disease test; and Cancerguard, a multi-cancer early detection blood test.

Abbott said the Exact Sciences team adds a pipeline of next-generation products aimed at earlier cancer detection, treatment optimization and ongoing monitoring. Following these announcements, the company's shares moved -1.43%, and are now trading at a price of $121.76. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.